Form 4: Director Timothy Coughlin Executes Stock Option Exercise

Travere Therapeutics Director Timothy Coughlin exercised 10,000 stock options and sold the resulting shares via a 10b5-1 plan.

Summary

• Director Timothy Coughlin exercised 10,000 stock options at a strike price of $26.52.
• Following the exercise, the director sold 10,000 shares of common stock at a weighted average price of $50.0747.
• The sale was executed under a pre-established Rule 10b5-1(c) trading plan adopted on November 19, 2025.
• The director's total beneficial ownership in Travere Therapeutics stands at 56,250 shares post-transaction.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was executed through a pre-planned 10b5-1 program, which is a routine administrative action for corporate insiders.

Positives

• The transaction was conducted under a pre-planned Rule 10b5-1(c) arrangement, indicating the sale was not based on immediate non-public information.
• The exercise of options demonstrates the director's continued participation in the company's equity incentive programs.

Negatives

• The transaction results in a net reduction of the director's direct shareholding by 10,000 shares compared to the pre-exercise balance.

Risks

• Reliance on Rule 10b5-1 plans does not eliminate market risk or the potential for negative investor perception regarding insider selling.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Industry Context

StockSavvy.ai notes that insider selling via 10b5-1 plans is a standard corporate governance practice for executives and directors to diversify holdings while maintaining compliance with securities laws.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for biotech directors to avoid allegations of insider trading.
• The transaction volume is relatively small compared to the total outstanding shares of Travere Therapeutics.

Stakeholder Impact

• Minimal impact on shareholders as the transaction was pre-planned and represents a small portion of the director's holdings.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

Travere Therapeutics, TVTX, Insider Trading, Form 4, Stock Options, Director Transaction